Lupus Treatment Advances: Agents in the Pipeline

Video

Novel therapies in the pipeline that demonstrate potential advantages when used as treatment for systemic lupus erythematosus and lupus nephritis.

Related Videos
Related Content
Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg

Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg

April 17th 2024
Article
Emerging Agents in the Treatment of Rheumatic Diseases

Emerging Agents in the Treatment of Rheumatic Diseases

October 2nd 2023
Podcast
FDA Grants Nipocalimab Fast Track Designation for Rare Fetal Disease, with Katie Abouzahr, MD

FDA Grants Nipocalimab Fast Track Designation for Rare Fetal Disease, with Katie Abouzahr, MD

April 5th 2024
Article
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

August 31st 2023
Podcast
Vibeke Strand, MD | Credit: Prime Education

Deucravacitinib Improves Patient-Reported Outcomes in Active Psoriatic Arthritis

March 27th 2024
Article
Febuxostat Use Among Gout Asian Patients Linked to Increased Cardiovascular Risk

Febuxostat Use Among Gout Asian Patients Linked to Increased Cardiovascular Risk

March 27th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.